<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3003">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04771013</url>
  </required_header>
  <id_info>
    <org_study_id>AEC-01-2021</org_study_id>
    <secondary_id>COM-2020-01</secondary_id>
    <secondary_id>AEC-01-2021</secondary_id>
    <nct_id>NCT04771013</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Thymic Peptides in the Treatment of Hospitalized COVID-19 Patients in Honduras</brief_title>
  <official_title>A Single-arm, Open-Label, Phase II Clinical Study to Evaluate the Safety and Efficacy of Thymic Peptides in the Treatment of Hospitalized COVID-19 Patients in Honduras</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Católica de Honduras</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pontificia Universidad Catolica de Chile</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad Católica de Honduras</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm, open-label, phase II clinical study to evaluate the safety and efficacy&#xD;
      of thymic peptides in the treatment of hospitalized COVID-19 patients in Honduras.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was approved and registered by the Dirección General de Vigilancia del Marco&#xD;
      Normativo de la Secretaría de Salud de Honduras (General Directorate for Regulatory Framework&#xD;
      Surveillance of the Ministry of Health of Honduras) the eight of February of 2021; enrollment&#xD;
      began tenth of February of 2021.&#xD;
&#xD;
      The study will analyze 23 clinical parameters, 9 laboratory studies besides complete blood&#xD;
      count, chest radiography, time to response, adverse clinical outcomes, and hospital length of&#xD;
      stay in 20 participants treated with a daily oral dose of 250 mg of lyophilized thymic&#xD;
      peptides dissolved in 50 mL of water (one hour before or two hours after a meal) in addition&#xD;
      to the standard treatment. A participant-level comparison based on registry data from&#xD;
      Hospital de Santa Bárbara Integrado will be performed after propensity score matching. The&#xD;
      Generic Assessment of Side Effects in Clinical Trials (GASE) will be applied in addition to&#xD;
      monitoring of treatment-emergent adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2021</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>A participant-level comparison based on registry data from the Hospital de Santa Bárbara Integrado will be performed after propensity score matching.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Participant Response</measure>
    <time_frame>During hospitalization for up to 20 days.</time_frame>
    <description>Measured in days to clinical response that will be defined as clinical stability (temperature, ≤37.8°C; heart rate, ≤100 beats per min; systolic blood pressure, ≥90 mm Hg; respiratory rate, ≤24 breaths per min; oxygen saturation, ≥90 percent; normal mental status; no receipt of supplemental oxygen by face mask or mechanical ventilation) with improvement in at least one symptom (anosmia, dysgeusia, cough, shortness of breath, cyanosis, conjunctivitis, pharyngitis, sputum production, rhinorrhea, myalgia, otalgia, odynophagia, fatigue, diarrhea, hemoptysis, vomit) and with no symptom worsening that is sustained for at least 24 h.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Treatment Related Adverse Events as Assessed by the Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v5.0)</measure>
    <time_frame>Up to 20 days</time_frame>
    <description>Number of participants who experience adverse events ≥ Grade 3, as defined by the CTCAE v5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Treatment Related Side Effects as Assessed by the General Assessment of Side Effects (GASE)</measure>
    <time_frame>Up to 20 days</time_frame>
    <description>Number of participants who experience severe side effects as defined by the GASE.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital Average Length of Stay (ALOS) as Measured by the Mean Participants' Inpatient Days</measure>
    <time_frame>Up to 20 days</time_frame>
    <description>The average length of stay will be calculated by dividing the sum of inpatient days by the number of participant admissions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Defined as the Time From the Start of Treatment until Death due to any Reason</measure>
    <time_frame>Up to 20 days</time_frame>
    <description>Time for overall survival will be measured in days.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Daily oral dose of thymic peptides</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a daily oral dose of 250 mg of lyophilized thymic peptides dissolved in 50 mL of water (one hour before or two hours after a meal) in addition to the standard treatment, for up to 20 days or until medical discharge.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Thymic peptides</intervention_name>
    <description>250 mg oral daily dose of lyophilized thymic peptides dissolved in 50 mL of water, administered with an empty stomach.</description>
    <arm_group_label>Daily oral dose of thymic peptides</arm_group_label>
    <other_name>Unicahsina</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed case of COVID-19 by viral nucleic acid (RNA) detection, viral antigen&#xD;
             detection, or detection of antibodies to the virus.&#xD;
&#xD;
          -  Participants that require hospitalization under Honduran Ministry of Health Guidelines&#xD;
             for Clinical Management of COVID-19 Adult Patients: Stage IIb, defined as a patient&#xD;
             with or without risk factors that presents with warning signs (shortness of breath,&#xD;
             tachypnea), and altered inflammatory parameters.&#xD;
&#xD;
          -  Participants that present with at least one of the following: oxygen saturation level&#xD;
             below 94 percent; complete blood count showing lymphopenia, neutrophilia, or both;&#xD;
             positive C-reactive protein; chest radiography or CT scan with ground-glass opacities.&#xD;
&#xD;
          -  Male or female at least 21 years old.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  COVID-19 patients that do not require hospitalization under Honduran Ministry of&#xD;
             Health Guidelines for Clinical Management of COVID-19 Adult Patients: phase IA&#xD;
             (asymptomatic), phase IB (mild symptoms without risk factors), or phase IC (mild&#xD;
             symptoms with risk factors).&#xD;
&#xD;
          -  Participants currently in other clinical trials evaluating experimental drugs.&#xD;
&#xD;
          -  Known history of allergic reactions to thymic peptides or calf thymus acid lysate&#xD;
             derivatives.&#xD;
&#xD;
          -  Organ transplant recipients.&#xD;
&#xD;
          -  Women who are pregnant or breast feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Héctor M Ramos, MD</last_name>
    <role>Study Director</role>
    <affiliation>Universidad Católica de Honduras; Pontificia Universidad Católica de Chile</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karla G Reyes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad Católica de Honduras; Universidad Mayor</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nelson A Espinoza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad Católica de Honduras</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Héctor M Ramos, MD</last_name>
    <phone>+56934988958</phone>
    <email>hramos@unicah.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de Santa Bárbara Integrado</name>
      <address>
        <city>Santa Bárbara</city>
        <zip>22101</zip>
        <country>Honduras</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Héctor M Ramos, MD</last_name>
      <phone>+56934988958</phone>
      <email>hramos@unicah.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>Honduras</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 24, 2021</study_first_submitted>
  <study_first_submitted_qc>February 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2021</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Católica de Honduras</investigator_affiliation>
    <investigator_full_name>Héctor Miguel Ramos Zaldívar</investigator_full_name>
    <investigator_title>Director of the Catholic University of Honduras Medical Research Group (GIMUNICAH)</investigator_title>
  </responsible_party>
  <keyword>SARS-CoV-2 Infection</keyword>
  <keyword>COVID-19 Pandemic</keyword>
  <keyword>2019 Novel Coronavirus Disease</keyword>
  <keyword>Thymic peptides</keyword>
  <keyword>Thymus gland</keyword>
  <keyword>Peptides</keyword>
  <keyword>Honduras</keyword>
  <keyword>Coronavirus Disease 2019</keyword>
  <keyword>Coronavirus Disease-19</keyword>
  <keyword>COVID-19 Virus Infection</keyword>
  <keyword>2019-nCoV Disease</keyword>
  <keyword>2019-nCoV Infection</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All of the individual participant data collected during the trial, after deidentification.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Beginning 3 months and ending 5 years following article publication.</ipd_time_frame>
    <ipd_access_criteria>Investigators whose proposed use of the data has been approved by an independent review committee (&quot;learned intermediary&quot;) identified for this purpose.&#xD;
For individual participant data meta-analysis.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

